GlaxoSmithKline Pharmaceuticals Ltd appoints Bhushan Akshikar as MD

Bhushan Akshikar

GlaxoSmithKline Pharmaceuticals Limited announced the appointment of Bhushan Akshikar as Managing Director of the company, with effect from December 1, 2022. He succeeds Sridhar Venkatesh, who is moving to a senior role within GSK Group.

According to the company’s exchange filing, “The Board of Directors of the Company at its meeting held today, has appointed Mr. Bhushan Akshikar as a Managing Director of the Company for period of four years effective 1st December 2022. He succeeds Mr. Sridhar Venkatesh who is moving to a new senior role within GSK Group effective 1st December 2022.”

Bhushan Akshikar is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry.

Bhushan joined GSK India in September 2011 to lead the specialty and commercial excellence business units. In 2014, he was appointed Head of the Mass Markets business. He was subsequently elevated as the Managing Director of the publicly listed entity of GSK in Nigeria, Africa in end- 2016. Apart from a strong business turn-around, he also built a high performing, resilient team. He then moved to Turkey in 2019 to lead GSK’s Vaccines business to drive strategic initiatives and launches in both private and tender segments in the Middle East, Russia CIS & Africa region.

In December 2020, he returned to India as the Commercial Head of the General Medicines business and has led a cultural transformation journey for the large INR 2500+ crores General Medicines business. He has built a strong leadership pipeline reflecting in leadership position and improved competitive performance of several flagship brands of GSK.

+ posts

HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.

What's your take on this post ? Comment: